162 related articles for article (PubMed ID: 11437159)
1. Study of binding and neutralising antibodies to interferon-beta in two groups of relapsing-remitting multiple sclerosis patients.
Fernández O; Mayorga C; Luque G; Guerrero M; Guerrero R; Leyva L; León A; Blanca M
J Neurol; 2001 May; 248(5):383-8. PubMed ID: 11437159
[TBL] [Abstract][Full Text] [Related]
2. Discordant effect of IFN-beta1a therapy on anti-IFN antibodies and thyroid disease development in patients with multiple sclerosis.
Monzani F; Meucci G; Caraccio N; Saviozzi M; Casolaro A; Moscato G; Lombardo F; Mosti S; Scagnolari C; Bruschi F; Antonelli G; Ferrannini E; Murri L
J Interferon Cytokine Res; 2002 Jul; 22(7):773-81. PubMed ID: 12184915
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity and tolerability of an investigational formulation of interferon-beta1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis.
Giovannoni G; Barbarash O; Casset-Semanaz F; Jaber A; King J; Metz L; Pardo G; Simsarian J; Sørensen PS; Stubinski B;
Clin Ther; 2007 Jun; 29(6):1128-45. PubMed ID: 17692727
[TBL] [Abstract][Full Text] [Related]
4. Neutralizing antibodies to interferon.
Noronha A
Neurology; 2007 Jun; 68(24 Suppl 4):S16-22. PubMed ID: 17562846
[TBL] [Abstract][Full Text] [Related]
5. Interferon-beta (INF-beta) antibodies in interferon-beta1a- and interferon-beta1b-treated multiple sclerosis patients. Prevalence, kinetics, cross-reactivity, and factors enhancing interferon-beta immunogenicity in vivo.
Perini P; Facchinetti A; Bulian P; Massaro AR; Pascalis DD; Bertolotto A; Biasi G; Gallo P
Eur Cytokine Netw; 2001 Mar; 12(1):56-61. PubMed ID: 11282547
[TBL] [Abstract][Full Text] [Related]
6. Optimising MS disease-modifying therapies: antibodies in perspective.
Giovannoni G
J Neurol; 2004 Sep; 251 Suppl 5():v30-v35. PubMed ID: 15549353
[TBL] [Abstract][Full Text] [Related]
7. Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta-1b.
Antonelli G; Simeoni E; Bagnato F; Pozzilli C; Turriziani O; Tesoro R; Di Marco P; Gasperini C; Fieschi C; Dianzani F
J Neurol Sci; 1999 Oct; 168(2):131-6. PubMed ID: 10526196
[TBL] [Abstract][Full Text] [Related]
8. Are ex vivo neutralising antibodies against IFN-beta always detrimental to therapeutic efficacy in multiple sclerosis?
Sorensen PS; Koch-Henriksen N; Bendtzen K
Mult Scler; 2007 Jun; 13(5):616-21. PubMed ID: 17548440
[TBL] [Abstract][Full Text] [Related]
9. Epitope specificity of neutralizing antibodies against IFN-beta.
Gneiss C; Reindl M; Berger T; Lutterotti A; Ehling R; Egg R; Deisenhammer F
J Interferon Cytokine Res; 2004 May; 24(5):283-90. PubMed ID: 15153311
[TBL] [Abstract][Full Text] [Related]
10. A sensitive radioimmunoprecipitation assay for assessing the clinical relevance of antibodies to IFN beta.
Lawrence N; Oger J; Aziz T; Palace J; Vincent A
J Neurol Neurosurg Psychiatry; 2003 Sep; 74(9):1236-9. PubMed ID: 12933925
[TBL] [Abstract][Full Text] [Related]
11. Correlation between anti-interferon-β binding and neutralizing antibodies in interferon-β-treated multiple sclerosis patients.
Jensen PE; Sellebjerg F; Søndergaard HB; Sørensen PS
Eur J Neurol; 2012 Oct; 19(10):1311-7. PubMed ID: 22564111
[TBL] [Abstract][Full Text] [Related]
12. Biological activity of interferon betas in patients with multiple sclerosis is affected by treatment regimen and neutralising antibodies.
Bertolotto A; Sala A; Malucchi S; Marnetto F; Caldano M; Di Sapio A; Capobianco M; Gilli F
J Neurol Neurosurg Psychiatry; 2004 Sep; 75(9):1294-9. PubMed ID: 15314118
[TBL] [Abstract][Full Text] [Related]
13. CD45RA+ ICAM-3+ lymphocytes in interferon-beta1b-treated and -untreated patients with relapsing-remitting multiple sclerosis.
Chatzimanolis N; Kraus J; Bauer R; Engelhardt B; Bregenzer T; Kuehne BS; Tofighi J; Laske C; Stolz E; Blaes F; Voigt K; Traupe H; Kaps M; Oschmann P
Acta Neurol Scand; 2004 Dec; 110(6):377-85. PubMed ID: 15527450
[TBL] [Abstract][Full Text] [Related]
14. [The formation and significance of antibodies to interferon beta during immunomodulating treatment of multiple sclerosis].
Bartosik-Psujek H; Stelmasiak Z
Neurol Neurochir Pol; 2004; 38(1 Suppl 1):S53-6. PubMed ID: 15045868
[TBL] [Abstract][Full Text] [Related]
15. Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development.
Hegen H; Millonig A; Bertolotto A; Comabella M; Giovanonni G; Guger M; Hoelzl M; Khalil M; Killestein J; Lindberg R; Malucchi S; Mehling M; Montalban X; Polman CH; Rudzki D; Schautzer F; Sellebjerg F; Sørensen PS; Deisenhammer F
Mult Scler; 2014 Apr; 20(5):577-87. PubMed ID: 24009164
[TBL] [Abstract][Full Text] [Related]
16. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study.
Kappos L; Clanet M; Sandberg-Wollheim M; Radue EW; Hartung HP; Hohlfeld R; Xu J; Bennett D; Sandrock A; Goelz S;
Neurology; 2005 Jul; 65(1):40-7. PubMed ID: 16009883
[TBL] [Abstract][Full Text] [Related]
17. The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis.
Koch-Henriksen N; Sorensen PS; Bendtzen K; Flachs EM
Mult Scler; 2009 May; 15(5):601-5. PubMed ID: 19299439
[TBL] [Abstract][Full Text] [Related]
18. Reduced effectiveness of long-term interferon-beta treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based study.
Boz C; Oger J; Gibbs E; Grossberg SE;
Mult Scler; 2007 Nov; 13(9):1127-37. PubMed ID: 17967840
[TBL] [Abstract][Full Text] [Related]
19. Serial analysis of soluble intercellular adhesion molecule-1 level in relapsing-remitting multiple sclerosis patients during IFN-beta1b treatment.
Kilinc M; Saatci-Cekirge I; Karabudak R
J Interferon Cytokine Res; 2003 Mar; 23(3):127-33. PubMed ID: 12716484
[TBL] [Abstract][Full Text] [Related]
20. Measuring and management of anti-interferon beta antibodies in subjects with multiple sclerosis.
Farrell RA; Giovannoni G
Mult Scler; 2007 Jun; 13(5):567-77. PubMed ID: 17548434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
